Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. While ∼50% of patients with HCM carry a sarcomere gene mutation (sarcomere mutation-positive, SMP), the genetic background is unknown in the other half of the patients (sarcomere mutation-negative, SMN). Gene mutations are most often present in genes encoding the sarcomere proteins myosin heavy chain, myosin-binding protein C, and troponin T. Studies in cardiac tissue samples from patients with obstructive HCM that were obtained during myectomy surgery showed increased myofilament calcium sensitivity, increased kinetics and tension cost, and a reduction of the super-relaxed state of myosin, which is associated with an energy-conserving status of the crossbridges. The increase in myofilament calcium sensitivity is observed at a low dose of mutant protein, while the magnitude of the increase in calcium sensitivity depends on the specific mutation location. These mutation-mediated myofilament changes may underlie inefficient in vivo cardiac performance in mutation carriers. Reduced cardiac efficiency has been observed before onset of cardiac hypertrophy and at advanced disease stages. In addition, impaired diastolic function is an early disease characteristic of HCM. Our recent proteomics studies revealed increased detyrosination of microtubules, which may be a cause of diastolic dysfunction. Recent treatments that target inefficient cardiac performance, such as myosin inhibitors and metabolic drug therapies, may have the potential to prevent, delay, or even reverse disease in HCM-mutation carriers. Treatment response may depend on the specific gene mutation in SMP individuals and may explain diverse response of HCM patients to therapy. While mutation-mediated cardiomyocyte defects have become clear in past years, more research is warranted to define the cellular pathomechanisms of cardiac dysfunction in SMN patients.
Skip Nav Destination
Article navigation
Meeting Abstract|
E–C Coupling Meeting 2021|
November 12 2021
Cardiac muscle disease and therapeutic targets: Calcium Signaling and Excitation–Contraction in Cardiac, Skeletal and Smooth Muscle
Maike Schuldt,
Maike Schuldt
1Department of Physiology, Amsterdam UMC, Amsterdam, Netherlands
Search for other works by this author on:
Larissa Dorsch,
Larissa Dorsch
1Department of Physiology, Amsterdam UMC, Amsterdam, Netherlands
Search for other works by this author on:
Diederik Kuster,
Diederik Kuster
1Department of Physiology, Amsterdam UMC, Amsterdam, Netherlands
Search for other works by this author on:
Jolanda Van der Velden
Jolanda Van der Velden
1Department of Physiology, Amsterdam UMC, Amsterdam, Netherlands
Search for other works by this author on:
Maike Schuldt
1Department of Physiology, Amsterdam UMC, Amsterdam, Netherlands
Larissa Dorsch
1Department of Physiology, Amsterdam UMC, Amsterdam, Netherlands
Diederik Kuster
1Department of Physiology, Amsterdam UMC, Amsterdam, Netherlands
Jolanda Van der Velden
1Department of Physiology, Amsterdam UMC, Amsterdam, Netherlands
Online Issn: 1540-7748
Print Issn: 0022-1295
© 2021 Schuldt et al.
2021
This article is available under a Creative Commons License (Attribution–Noncommercial–Share
Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
J Gen Physiol (2022) 154 (9): e2021ecc47.
Citation
Maike Schuldt, Larissa Dorsch, Diederik Kuster, Jolanda Van der Velden; Cardiac muscle disease and therapeutic targets: Calcium Signaling and Excitation–Contraction in Cardiac, Skeletal and Smooth Muscle. J Gen Physiol 5 September 2022; 154 (9): e2021ecc47. doi: https://doi.org/10.1085/jgp.2021ecc47
Download citation file:
1,130
Views
Suggested Content
The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM
J Gen Physiol (December,2018)
E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction
J Gen Physiol (August,2013)
cMyBP-C ablation in human engineered cardiac tissue causes progressive Ca2+-handling abnormalities
J Gen Physiol (March,2023)
Email alerts
Advertisement